School of Education

Permanent URI for this community

https://ds.dmiseu.org/handle/123456789/12

Browse

Browsing School of Education by Subject "Apoptosis inducing factor"

Now showing 1 - 1 of 1
  • No Thumbnail Available
    Item
    In Silico Drug Design in Human Apotosis Inducing Factor(AIF) in Lund Cancer
    (Journal of Emerging Technologies and Innovative Research (JETIR), 2025) Murugesan, Anbu Megala
    The malignant condition known as lung cancer is characterized by unchecked growth in the lung's tissues or cells. This aberrant growth develops into a tumour known as a carcinoma. If it is not appropriately or quickly treated, it may metastasize to other areas of the body. In multicellular organisms, apoptosis is a process of programmed cell death in which the cell goes through a sequence of biochemical events that promote cell development, eliminate undesirable cells, preserve tissue integrity, and stop the spread of cancer. It is the cell's method of carrying out a controlled suicide. The cell shrinks, develops blebs, and breaks apart its DNA during apoptosis. Apoptotic cell mutations can result in tissue damage, tumour growth, unchecked cell division, and neurodegenerative diseases. causing apoptosis. Mutations in apoptotic cells can lead to uncontrolled cell proliferation, tumor development, tissue damage, and neurodegenerative disorders. Apoptosis-inducing factor (AIF) is a mitochondrial protein involved in both caspase-dependent and caspase-independent apoptosis pathways. AIF was initially characterized as a cell death mediator and plays an important role in lung cancer. Coiled-Coil-Helix, domain containing Protein 4, or CHCHD4, is involved in oxidative stress regulation and mitochondrial health maintenance. CHCHD4 plays a role in the cellular reaction to damage by interacting with proteins in the inner membrane of the mitochondria. CHCHD4 may have an impact on lung cancer cell survival, particularly in the presence of oxidative stress, which is typical of cancer cells. Computer-aided drug design (CADD), also known as in silico drug design, is a computational method that uses bioinformatics tools to find molecules that resemble drugs. The biological and physicochemical characteristics of possible drug candidates are analysed and predicted with the aid of these tools. Because it offers tools and techniques for analyzing vast amounts of biological data, forecasting drug-target interactions, modelling protein structures, and simulating molecular interactions, bioinformatics is essential to in-silico drug design. This research could pave the way for more effective therapies targeting mitochondrial functions and cell death pathways in cancer, bridging the gap between theoretical research and practical application in drug discovery to improve patient outcomes.